| Ytd | -26.37% | |
| 1y | -58.13% |
| Open | Prev Close | 1.32 | Low | High | Mkt Cap | 4.14M | |||
| Vol | 1.08K | Avg Vol | 146.66K | EPS | -3.87 | P/E | -0.34 | Forward P/E | -0.26 |
| Beta | 0.14 | Short Ratio | 1.03 | Inst. Own | 0.94% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-02 | 50-d Avg | 1.17 | 200-d Avg | 1.75 | 1yr Est | 32.00 |
ALZN News
Gainers Ernexa Therapeutics (NASDAQ:ERNA) stock increased by 88.3% to $11.41 during Wednesday's
Gainers Can Fite Biopharma (AMEX:CANF) stock moved upwards by 52.0% to $4.52 during Wednesday's
Gainers Alzamend Neuro (NASDAQ:ALZN) stock increased by 12.9% to $1.35 during Tuesday's after-m
Potentially Distinct Brain Profile: Across multiple brain regions, AL001 and lithium carbonate appea
Bioequivalence Confirmed: AL001 delivered 101% of total lithium blood exposure and 97% of peak lithi
Head-to-head studies of AL001 versus marketed lithium carbonate will compare lithium blood and brain
Shares of Alzamend Neuro, Inc. (NASDAQ: ALZN - Get Free Report) dropped 2.5% on Monday. The stock tr
Alzamend Neuro, Inc. (NASDAQ: ALZN - Get Free Report) shares were down 0.5% on Friday. The company t
Topline data expected in first quarter of 2026 Head-to-head studies of AL001 versus a marketed lithi
Session Topic is the I nnovation and Current Directions in Military Suicide Prevention, Research, an
During the year ended April 30, 2025, net cash provided by financing activities was $10.4 million St
ATLANTA, June 16, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clini
Topline data expected by year end Head-to-head studies of AL001 versus a marketed lithium carbonate
Topline data expected by year end Head-to-head studies of AL001 versus a marketed lithium carbonate
Topline data expected by year end Head-to-head studies of AL001 versus a marketed lithium carbonate
Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comp
After losing some value lately, a hammer chart pattern has been formed for Alzamend Neuro (ALZN), in
ATLANTA, March 25, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clin
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial for Next-Gen Lithium Treatment o
ATLANTA, March 11, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clin
ATLANTA, March 04, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clin
ATLANTA, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clini
Here is how Alzamend Neuro, Inc. (ALZN) and Beam Therapeutics Inc. (BEAM) have performed compared to
On Tuesday, 386 stocks made new 52-week lows.
Tuesday's session saw 729 companies set new 52-week lows.